| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiemetics | 73 | 2023 | 98 | 21.180 |
Why?
|
| Nausea | 84 | 2023 | 175 | 20.920 |
Why?
|
| Vomiting | 84 | 2023 | 193 | 20.340 |
Why?
|
| Antineoplastic Agents | 54 | 2023 | 2360 | 7.430 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 22 | 2019 | 34 | 5.700 |
Why?
|
| Quinuclidines | 17 | 2023 | 26 | 3.840 |
Why?
|
| Isoquinolines | 15 | 2023 | 72 | 3.510 |
Why?
|
| Benzodiazepines | 15 | 2022 | 65 | 3.330 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 15 | 2019 | 18 | 3.290 |
Why?
|
| Neoplasms | 36 | 2023 | 2898 | 3.260 |
Why?
|
| Spiro Compounds | 8 | 2019 | 25 | 2.920 |
Why?
|
| Morpholines | 14 | 2018 | 65 | 2.490 |
Why?
|
| Serotonin Antagonists | 10 | 2013 | 35 | 1.900 |
Why?
|
| Cisplatin | 20 | 2023 | 612 | 1.700 |
Why?
|
| Dexamethasone | 21 | 2023 | 326 | 1.620 |
Why?
|
| Polysorbates | 2 | 2018 | 3 | 1.330 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 199 | 1.220 |
Why?
|
| Humans | 117 | 2023 | 86644 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 2438 | 1.120 |
Why?
|
| Ondansetron | 13 | 2019 | 21 | 0.890 |
Why?
|
| Double-Blind Method | 22 | 2023 | 1823 | 0.860 |
Why?
|
| Pyridines | 4 | 2021 | 310 | 0.860 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2021 | 172 | 0.810 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 894 | 0.800 |
Why?
|
| Metoclopramide | 5 | 2013 | 16 | 0.770 |
Why?
|
| Receptors, Neurokinin-1 | 6 | 2023 | 14 | 0.770 |
Why?
|
| Quality of Life | 13 | 2019 | 1585 | 0.760 |
Why?
|
| Clinical Trials as Topic | 11 | 2018 | 1169 | 0.730 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 6509 | 0.730 |
Why?
|
| Fluid Therapy | 1 | 2020 | 50 | 0.730 |
Why?
|
| Aged | 41 | 2021 | 18415 | 0.700 |
Why?
|
| Middle Aged | 49 | 2021 | 25028 | 0.690 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 193 | 0.680 |
Why?
|
| Hospice Care | 3 | 2005 | 39 | 0.680 |
Why?
|
| Guideline Adherence | 1 | 2020 | 223 | 0.650 |
Why?
|
| Cyclophosphamide | 11 | 2023 | 299 | 0.650 |
Why?
|
| Female | 57 | 2023 | 44533 | 0.610 |
Why?
|
| Adult | 41 | 2021 | 25648 | 0.590 |
Why?
|
| Male | 54 | 2023 | 40966 | 0.550 |
Why?
|
| Neurotransmitter Agents | 2 | 2006 | 106 | 0.500 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2021 | 176 | 0.490 |
Why?
|
| Granisetron | 7 | 2016 | 8 | 0.480 |
Why?
|
| Antifungal Agents | 2 | 2005 | 117 | 0.470 |
Why?
|
| Piperazines | 3 | 2009 | 272 | 0.420 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 4 | 2015 | 15 | 0.400 |
Why?
|
| Induction Chemotherapy | 5 | 2018 | 147 | 0.390 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 301 | 0.380 |
Why?
|
| Anorexia | 2 | 2009 | 30 | 0.370 |
Why?
|
| Drug Combinations | 3 | 2023 | 224 | 0.370 |
Why?
|
| Piperidines | 2 | 2009 | 181 | 0.370 |
Why?
|
| Appetite Stimulants | 1 | 2009 | 1 | 0.360 |
Why?
|
| Megestrol Acetate | 1 | 2009 | 10 | 0.360 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 2903 | 0.350 |
Why?
|
| Drug Administration Schedule | 7 | 2021 | 916 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 3 | 2005 | 746 | 0.350 |
Why?
|
| Bone Marrow Transplantation | 5 | 1999 | 286 | 0.350 |
Why?
|
| Antipsychotic Agents | 3 | 2017 | 123 | 0.330 |
Why?
|
| Administration, Oral | 8 | 2021 | 684 | 0.330 |
Why?
|
| Anthracyclines | 7 | 2023 | 37 | 0.320 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 19 | 0.320 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 257 | 0.310 |
Why?
|
| Disease Management | 2 | 2020 | 327 | 0.310 |
Why?
|
| Fluoxetine | 1 | 2007 | 42 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2016 | 1961 | 0.300 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8489 | 0.300 |
Why?
|
| Prospective Studies | 7 | 2023 | 4214 | 0.300 |
Why?
|
| Radiotherapy | 2 | 2020 | 328 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 865 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 1036 | 0.270 |
Why?
|
| Animals | 20 | 2019 | 26582 | 0.260 |
Why?
|
| Mycoses | 1 | 2005 | 46 | 0.260 |
Why?
|
| Patient Satisfaction | 4 | 2003 | 455 | 0.250 |
Why?
|
| Infusions, Intravenous | 6 | 2019 | 429 | 0.250 |
Why?
|
| Treatment Outcome | 7 | 2023 | 7993 | 0.240 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1939 | 0.240 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 106 | 0.240 |
Why?
|
| Depression | 1 | 2007 | 473 | 0.240 |
Why?
|
| Bacterial Infections | 1 | 2005 | 182 | 0.230 |
Why?
|
| Doxorubicin | 5 | 2013 | 295 | 0.230 |
Why?
|
| Injections, Intravenous | 5 | 2019 | 244 | 0.230 |
Why?
|
| Cardiovascular System | 1 | 2003 | 71 | 0.220 |
Why?
|
| Quinolizines | 5 | 2003 | 6 | 0.210 |
Why?
|
| Education, Premedical | 1 | 2001 | 1 | 0.210 |
Why?
|
| International Educational Exchange | 1 | 2001 | 6 | 0.210 |
Why?
|
| Electrocardiography | 2 | 2003 | 478 | 0.210 |
Why?
|
| Indoles | 6 | 2013 | 318 | 0.200 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 50 | 0.200 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 161 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 159 | 0.190 |
Why?
|
| Terminally Ill | 1 | 2000 | 23 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 839 | 0.190 |
Why?
|
| Complementary Therapies | 1 | 2020 | 54 | 0.170 |
Why?
|
| United States | 7 | 2020 | 6672 | 0.170 |
Why?
|
| Prisoners | 1 | 1999 | 40 | 0.170 |
Why?
|
| Acetals | 1 | 1999 | 3 | 0.170 |
Why?
|
| Area Under Curve | 1 | 2019 | 334 | 0.170 |
Why?
|
| Half-Life | 2 | 2017 | 96 | 0.170 |
Why?
|
| Carboplatin | 1 | 2019 | 286 | 0.170 |
Why?
|
| Palliative Care | 1 | 2000 | 257 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 426 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 173 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 454 | 0.160 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 141 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 108 | 0.150 |
Why?
|
| Thalidomide | 1 | 2017 | 54 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 410 | 0.150 |
Why?
|
| Risk Factors | 4 | 2010 | 5417 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 1169 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 72 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 636 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 380 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2019 | 563 | 0.130 |
Why?
|
| Serotonin | 3 | 2023 | 218 | 0.130 |
Why?
|
| Intestinal Neoplasms | 2 | 2005 | 56 | 0.130 |
Why?
|
| Molecular Structure | 1 | 2014 | 287 | 0.120 |
Why?
|
| Contrast Media | 1 | 2019 | 1078 | 0.120 |
Why?
|
| Consensus | 3 | 2023 | 335 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 645 | 0.110 |
Why?
|
| Cross-Linking Reagents | 1 | 2013 | 86 | 0.110 |
Why?
|
| Nucleotides | 1 | 2013 | 95 | 0.110 |
Why?
|
| Aromatase Inhibitors | 2 | 1996 | 28 | 0.110 |
Why?
|
| Appetite | 3 | 2009 | 26 | 0.110 |
Why?
|
| Conserved Sequence | 1 | 2013 | 210 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 193 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 114 | 0.100 |
Why?
|
| Oxygen Consumption | 7 | 1992 | 239 | 0.100 |
Why?
|
| Blood Component Transfusion | 1 | 2011 | 13 | 0.100 |
Why?
|
| Thrombelastography | 1 | 2011 | 47 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 350 | 0.100 |
Why?
|
| Safety | 2 | 2010 | 152 | 0.100 |
Why?
|
| Thromboplastin | 1 | 2010 | 7 | 0.100 |
Why?
|
| Nitriles | 1 | 1991 | 149 | 0.100 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 4 | 0.100 |
Why?
|
| Endotoxemia | 1 | 2010 | 18 | 0.100 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2010 | 15 | 0.100 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 63 | 0.090 |
Why?
|
| Imidazoles | 1 | 1991 | 162 | 0.090 |
Why?
|
| Blood Proteins | 3 | 1978 | 144 | 0.090 |
Why?
|
| Remission Induction | 5 | 2018 | 722 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 971 | 0.090 |
Why?
|
| Data Collection | 2 | 2001 | 372 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2011 | 268 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 155 | 0.090 |
Why?
|
| Adolescent | 8 | 2021 | 8981 | 0.090 |
Why?
|
| Body Weight | 2 | 2009 | 459 | 0.090 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 286 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2008 | 17 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Contraindications | 1 | 2008 | 72 | 0.080 |
Why?
|
| Fibromyalgia | 1 | 2008 | 14 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 104 | 0.080 |
Why?
|
| Placebos | 1 | 2007 | 218 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 408 | 0.080 |
Why?
|
| Anemia, Aplastic | 2 | 1984 | 30 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 148 | 0.080 |
Why?
|
| Child | 2 | 2017 | 6927 | 0.070 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2008 | 87 | 0.070 |
Why?
|
| Oxygen | 5 | 1978 | 726 | 0.070 |
Why?
|
| Neuropharmacology | 1 | 2006 | 2 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 3640 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3362 | 0.070 |
Why?
|
| Lung Neoplasms | 5 | 2009 | 2262 | 0.070 |
Why?
|
| Carbon Dioxide | 5 | 1992 | 188 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2008 | 158 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2006 | 45 | 0.070 |
Why?
|
| Cathepsin E | 1 | 2005 | 2 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 468 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 304 | 0.070 |
Why?
|
| Hypothermia | 1 | 1984 | 26 | 0.060 |
Why?
|
| Fadrozole | 2 | 1996 | 2 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2004 | 39 | 0.060 |
Why?
|
| Arterioles | 4 | 1981 | 22 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 138 | 0.060 |
Why?
|
| Carcinogens | 1 | 2004 | 108 | 0.060 |
Why?
|
| Arteries | 3 | 1981 | 176 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2005 | 181 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 191 | 0.060 |
Why?
|
| Adenoma | 1 | 2005 | 235 | 0.060 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 1983 | 6 | 0.060 |
Why?
|
| Heat Exhaustion | 1 | 1983 | 1 | 0.060 |
Why?
|
| Diffusion | 5 | 1978 | 93 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2003 | 35 | 0.060 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1983 | 58 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1983 | 11 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 1054 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 1 | 1983 | 72 | 0.060 |
Why?
|
| Camptothecin | 1 | 2004 | 189 | 0.060 |
Why?
|
| Infection Control | 1 | 1984 | 115 | 0.060 |
Why?
|
| Pia Mater | 2 | 1979 | 5 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Carcinoma | 1 | 2005 | 436 | 0.050 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1981 | 23 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 5976 | 0.050 |
Why?
|
| Lorazepam | 2 | 1993 | 16 | 0.050 |
Why?
|
| Diphenhydramine | 2 | 1993 | 17 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1851 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2001 | 23 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 3679 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 182 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 639 | 0.050 |
Why?
|
| Bone Marrow | 1 | 1983 | 435 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 1863 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2001 | 123 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 2 | 1978 | 212 | 0.050 |
Why?
|
| Brain | 3 | 2006 | 2216 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 782 | 0.040 |
Why?
|
| Fluorocarbons | 2 | 1978 | 72 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 204 | 0.040 |
Why?
|
| Headache | 2 | 1997 | 73 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 166 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 678 | 0.040 |
Why?
|
| Pancreas | 1 | 2019 | 239 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 996 | 0.040 |
Why?
|
| Bronchi | 1 | 1978 | 229 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 1999 | 306 | 0.040 |
Why?
|
| Skull | 1 | 1978 | 249 | 0.040 |
Why?
|
| Emetics | 1 | 2016 | 4 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1996 | 48 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 40 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 429 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1983 | 763 | 0.040 |
Why?
|
| Living Donors | 1 | 1999 | 339 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 328 | 0.040 |
Why?
|
| Dyssomnias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 394 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 107 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1981 | 621 | 0.030 |
Why?
|
| Capillaries | 2 | 1974 | 91 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1996 | 150 | 0.030 |
Why?
|
| Genes, APC | 2 | 2005 | 26 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 174 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 674 | 0.030 |
Why?
|
| Cats | 6 | 1981 | 303 | 0.030 |
Why?
|
| Diphosphonates | 1 | 1994 | 36 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1994 | 59 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 691 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 115 | 0.030 |
Why?
|
| Constipation | 1 | 1994 | 63 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1995 | 233 | 0.030 |
Why?
|
| Diarrhea | 1 | 1994 | 182 | 0.030 |
Why?
|
| Buffers | 1 | 2013 | 26 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 127 | 0.030 |
Why?
|
| Time Factors | 6 | 2004 | 5210 | 0.030 |
Why?
|
| Biotin | 1 | 2013 | 44 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2013 | 33 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 78 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 46 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2010 | 1924 | 0.030 |
Why?
|
| Nicotine | 1 | 1974 | 194 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1993 | 153 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 116 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 188 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2705 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2013 | 309 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 376 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2013 | 179 | 0.030 |
Why?
|
| Kinetics | 2 | 1992 | 1513 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 228 | 0.030 |
Why?
|
| Ligands | 1 | 2013 | 433 | 0.030 |
Why?
|
| Estrone | 1 | 1991 | 10 | 0.030 |
Why?
|
| Hydroxyprogesterones | 1 | 1991 | 22 | 0.030 |
Why?
|
| Androstenedione | 1 | 1991 | 29 | 0.030 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 1991 | 31 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2011 | 34 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2013 | 460 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 679 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1991 | 131 | 0.020 |
Why?
|
| Leukemia | 2 | 1983 | 320 | 0.020 |
Why?
|
| Menopause | 1 | 1991 | 71 | 0.020 |
Why?
|
| Aldosterone | 1 | 1991 | 65 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 456 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3092 | 0.020 |
Why?
|
| Thrombin | 1 | 2010 | 61 | 0.020 |
Why?
|
| Disease Progression | 2 | 2005 | 1531 | 0.020 |
Why?
|
| Estradiol | 1 | 1991 | 252 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1098 | 0.020 |
Why?
|
| Radiography | 2 | 1983 | 813 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1991 | 298 | 0.020 |
Why?
|
| Glucose | 1 | 1992 | 638 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1456 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2062 | 0.020 |
Why?
|
| Mice | 3 | 2010 | 11352 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 332 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 1968 | 16 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 134 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3030 | 0.020 |
Why?
|
| Erythrocytes | 2 | 1983 | 255 | 0.020 |
Why?
|
| Lung | 1 | 1974 | 1170 | 0.020 |
Why?
|
| Thymus Hormones | 1 | 1987 | 2 | 0.020 |
Why?
|
| Thymopoietins | 1 | 1987 | 7 | 0.020 |
Why?
|
| Proteins | 1 | 1993 | 777 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1987 | 220 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1540 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 1076 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 1987 | 365 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1978 | 493 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 79 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1987 | 464 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2002 | 1056 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1987 | 460 | 0.020 |
Why?
|
| Ranolazine | 1 | 2004 | 4 | 0.020 |
Why?
|
| Acetanilides | 1 | 2004 | 6 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1984 | 56 | 0.020 |
Why?
|
| Environment, Controlled | 1 | 1984 | 8 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 102 | 0.020 |
Why?
|
| Granulocytes | 1 | 1984 | 37 | 0.020 |
Why?
|
| Tuberculoma | 1 | 1983 | 2 | 0.020 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1983 | 24 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 94 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 879 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2004 | 81 | 0.010 |
Why?
|
| Spherocytes | 1 | 1983 | 1 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1983 | 23 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1983 | 79 | 0.010 |
Why?
|
| Rhenium | 1 | 1983 | 3 | 0.010 |
Why?
|
| Technetium | 1 | 1983 | 29 | 0.010 |
Why?
|
| Sulfur | 1 | 1983 | 28 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1984 | 157 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 270 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1983 | 48 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1984 | 123 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 552 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1983 | 220 | 0.010 |
Why?
|
| Necrosis | 1 | 1983 | 204 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1983 | 235 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2002 | 7 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 2 | 1978 | 32 | 0.010 |
Why?
|
| Liposomes | 1 | 2002 | 91 | 0.010 |
Why?
|
| Creatinine | 2 | 1993 | 338 | 0.010 |
Why?
|
| Neutrophils | 1 | 1983 | 307 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1753 | 0.010 |
Why?
|
| Critical Care | 1 | 1984 | 370 | 0.010 |
Why?
|
| Renal Artery | 1 | 1981 | 64 | 0.010 |
Why?
|
| Weight Loss | 2 | 1993 | 229 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1128 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 1075 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1981 | 231 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 859 | 0.010 |
Why?
|
| Brain Concussion | 1 | 1980 | 59 | 0.010 |
Why?
|
| Endothelium | 1 | 1979 | 59 | 0.010 |
Why?
|
| Solutions | 1 | 1978 | 85 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1978 | 74 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1984 | 1065 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1538 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 592 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1977 | 50 | 0.010 |
Why?
|
| Premedication | 1 | 1997 | 54 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1977 | 9 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1979 | 354 | 0.010 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 1977 | 14 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1984 | 3612 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2767 | 0.010 |
Why?
|
| Solubility | 1 | 1977 | 177 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 263 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1978 | 989 | 0.010 |
Why?
|
| Respiration | 1 | 1978 | 262 | 0.010 |
Why?
|
| Methotrexate | 1 | 1997 | 249 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1980 | 1143 | 0.010 |
Why?
|
| Postmenopause | 1 | 1996 | 98 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 826 | 0.010 |
Why?
|
| Chemistry | 1 | 1974 | 54 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1974 | 26 | 0.010 |
Why?
|
| Rats | 2 | 1978 | 3990 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1994 | 88 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1974 | 16 | 0.010 |
Why?
|
| Alpha-Globulins | 1 | 1974 | 11 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1974 | 28 | 0.010 |
Why?
|
| Membranes | 1 | 1974 | 36 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1974 | 24 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1974 | 96 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1974 | 130 | 0.010 |
Why?
|
| Calorimetry | 1 | 1993 | 15 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1993 | 34 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1974 | 135 | 0.010 |
Why?
|
| Glycine | 1 | 1993 | 92 | 0.010 |
Why?
|
| Hypoxia | 1 | 1978 | 641 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 1992 | 15 | 0.010 |
Why?
|
| Chlorides | 1 | 1993 | 103 | 0.010 |
Why?
|
| Hypertension | 1 | 1981 | 1141 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1992 | 83 | 0.010 |
Why?
|
| Heart Failure | 1 | 2002 | 1204 | 0.010 |
Why?
|
| Potassium | 1 | 1993 | 281 | 0.010 |
Why?
|
| Sodium | 1 | 1993 | 341 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1992 | 373 | 0.010 |
Why?
|
| Biological Transport | 1 | 1971 | 396 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1974 | 666 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1992 | 271 | 0.010 |
Why?
|
| Calcium | 1 | 1994 | 1156 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1993 | 770 | 0.010 |
Why?
|
| Microcirculation | 2 | 1980 | 106 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 873 | 0.000 |
Why?
|
| Vasodilation | 2 | 1978 | 96 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1968 | 197 | 0.000 |
Why?
|
| Thymopentin | 1 | 1987 | 2 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1987 | 25 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1987 | 171 | 0.000 |
Why?
|
| Graft Survival | 1 | 1987 | 884 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1981 | 135 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1981 | 503 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1980 | 44 | 0.000 |
Why?
|
| Hypotension | 1 | 1980 | 70 | 0.000 |
Why?
|
| Pentylenetetrazole | 1 | 1978 | 2 | 0.000 |
Why?
|
| Vasoconstriction | 1 | 1978 | 93 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1978 | 197 | 0.000 |
Why?
|
| Homeostasis | 1 | 1980 | 409 | 0.000 |
Why?
|
| Emulsions | 1 | 1977 | 19 | 0.000 |
Why?
|
| Seizures | 1 | 1978 | 297 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1978 | 584 | 0.000 |
Why?
|